LLY won FDA approval for Foundayo, an oral obesity GLP-1 pill, and is targeting 'billions' in sales. The approval boosted LLY shares and positions the company to rapidly close the gap with GLP-1 rivals, altering competitive dynamics in the booming obesity drug market.
LLY won FDA approval for Foundayo, an oral obesity GLP-1 pill, and is targeting 'billions' in sales. The approval boosted LLY shares and positions the company to rapidly close the gap with GLP-1 rivals, altering competitive dynamics in the booming obesity drug market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
extremely positive
Sentiment Score
0.90
Ticker Sentiment
